Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a single-center cross-sectional imaging and correlative biomarker study in patients
with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with
unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment
and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1
treatment prior to tumor resection or radiation. Blood sampling and tissue biopsies will be
collected from both cohorts and both cohorts will undergo two whole body PET(Positron
Emission Tomography)/CT(Computed Tomography) imaging with [18F]F-AraG. First scan prior to
initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment in
Cohort 1 and prior to tumor resection or radiation in Cohort 2